VolitionRx Announces Preparation Of Reimbursement Submission For Nu.Q Cancer Assays To Government Agencies In France
Benzinga Newsdesk 9 months ago
News
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL.